nice call Biobottom- it flopped right back stopped out again. With a stable market I still think she can run here into the shareholder meeting in hopes of new info coming out then.... maybe I'm just convincing myself/
isn't it something to see how AVNR rallied to the $1.60 line just before falling back for the close? http://finance.yahoo.com/charts#cha...hlc;crosshair=on;logscale=on;source=undefined a lot of time i just sit back and watch these stocks. some people watch soap operas. i watch the murky depths of busted biotechs. congrats to you on making some money off CBLI today. i wouldn't touch unless it sold off to previous resistance level, which is what? $8. i had to bite the bullet and take a HUGE loss today on a stock i let fall and didn't want to take the loss. i'm to embarrassed to even post its symbol. it's so obvious that the stock is in a downtrend and i had a chance to get of it at a decent price on a 1-day rally the day after they announced earnings Feb. 14. it's sickening to think about how much money i threw away. i bought and sold if based only on the short term support-resistance lines. the only bright spot of my trading this week was getting out of OVTI on Monday when it hit a limit order to sell @ $14.00 placed the week before immediately after buying it @ $13.00 and forgot about until i got the e-mail saying my order had been filled to sell the 1000 shares. that was an easy $980 made in a week. boy am i glad to be out of that piece of garbage. their CEO's English is incomprehensible and i can't listen to tonight's recorded CC. i'm just glad for the easy money i made last Monday for a 1-week hold period. i need to do more of that quick in and out trading. the week before i bought 1200 TFR @ $9.00 and sold it all at $9.45 just 3 days later.
AVNR is a stock i entered after it's collapse to $3 and exited at a loss, more or less soon afterward, when it kept falling. Look at the 5-yr chart and tell me it won't have a good bounce if it hits $1. Is this company vanishing into thin air? What's the reward:loss ratio here? What does the chart tell you? http://finance.yahoo.com/q/bc?s=AVNR&t=5y&l=on&z=l&q=l&c=
Oh Biobottom I gave it back at the end of the day. This is NOT GOOD DAYTRADING folks. Lots of whip saws!!!
Exactly! What did i say? "Too much Valium required"? Note this, though. March 7 is next week and CBLI is not in the running for the ARS procurement by HHS scheduled for March 7. See: --- from briefing (Not rated) 2-Mar-07 01:07 pm 13:04 HEPH Hollis-Eden Pharm: A name to watch on next week's expected HHS contract announcement (4.94 -0.18) HEPH is a name to watch next week, as the Department of Health and Human Services is expected to award its BioShield procurement contract on Wednesday, March 7. HEPH has submitted a proposal for its lead drug candidate Neumune to be included in a national stockpiling program under Project BioShield. Neumune is used to treat Acute Radiation Syndrome, which is a life-threatening condition resulting from exposure to high levels of radiation following a nuclear or radiological incident. Neumune is an investigational drug that is in development with the U.S. Department of Defense. The co has said there are currently no pharmaceuticals approved for use in protecting bone marrow from acute radiation syndrome. In November, HEPH noted that it was not aware of any other company that remained in the competitive range for this contract award. While the exact timing and dollar amount of the award are unknown, in a note on 1/16 Rodman & Renshaw said they estimate the award could be worth $50 mln... For a little background on the co's fundamentals, we note that HEPH is not yet profitable, but the single analyst estimate for 2007 is for the co to make $0.39 per share. The stock has experienced significant volatility in the past, but for the past year it has been confined to a $4-8 range. HEPH is fairly liquid, with average daily volume of ~264K shares and a float of ~21 mln shares. Short interest currently stands at 12% of the float. Mkt cap: $123 mln.
the only reason i can see for this trading is that it's a delayed IPO effect where big money is competing with daytraders to get a piece of the 11 M float. it's that same force that drove HEPH up to $36.
BIOB> HEPH Hollis-Eden Pharmaceuticals (NASDAQ GM) 3.02 -1.26 ( -29.44%) Why is this news not BETTER for CBLI I still have badly timed 900 shares which amazingly have turned into the green this news should of spiked this stock a lot more don't you think? I am oh so close to buying the S* out of it-- but does this US Gov rejection of HEPH reject CBLI's formulation as well? Are they that close? I am going to work out to try and clear my mind here it would be very much like me to blindly jump (hope) here on a past good idea that just looks today to have gotten a whole lot better. Thoughts?
you're just like a gambler throwing away money on a roulette wheel. listen to the HEPH conference call. it's going on now. DoD has been "co-developing" Neumune with DoD AFRRI since 1997. a DoD RFP for an ARS drug would make last month's CBLI 100% rally look like a pimple compared to the short squeeze you'd see in HEPH. my advice as a nuke-safety pro is to put a small bet on HEPH at under $3. when people realize that CBLI is only smoke and mirrors, they will dump it down to $1.
I have a question for Stoney, BBF or any others about this subject. I have been tracking CBLI for a few months now. I was wondering what your thoughts are on the following new from today (from MarketWatch.com story: http://www.marketwatch.com/News/Sto...x?guid={B463202B-FFAB-460C-9080-3DC863414A78}). The following quote to me seems to indicate that there must be other candidates that are being seriously considered by HHS: But, what I (we) don't seem to know is if CBLI's candidate drug is one of those being seriously considered. Does anyone here know which other candidates are being seriously considered. Is CBLI's "Protectan/CBLB502" one of those candidates? Is there any reason to believe or evidence to support the notion that in the HHS or DOD's procurement processes for an ARS drug, CBLI's drug might be the leading candidate (other than, perhaps, the stock price rally for CBLI in the past 2+ months)? Does anyone here know of a way of finding out all of the publically available information about the DOD & HHS procurement process for an ARS drug up to this point (other than google )? Any help or info (or well-reasoned opinion) you might offer would be greatly appreciated. Thanks. dI